VIII. Vaginalkarzinom

1. de Crevoisier R., Sanfilippo N., Gerbaulet A., Morice P., Pomel C., Castaigne D., Pautier P., Lhomme C., Duvillard P., Haie-meder C. Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiother Oncol 2007 Dec; 85(3):362-70
2. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., Garland S.M., Harper D.M.,Tang G.W., Ferris D.G., Steben M., Jones R.W., Bryan J., Taddeo F.J., Bautista O.M., Esser M.T., Sings H.L., Nelson M., Boslego J.W., Sattler C., Barr E., Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369:1693-702
3. Mock U., Kucera H., Fellner C., Knocke T.H., Pötter R. High-dose-rate (HDR) brachytherapy with or without external beam radiotherapy in the treatment of primary vaginal carcinoma: long-term results and side effects. Int J Radiat Oncol Biol Phys 2003 Jul 15; 56(4):950-7
4. Samant R., Lau B., E.C., Le T.,Tam T. Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. Int J Radiat Oncol Biol Phys 2007 Nov 1; 69(3):746-50